Day: October 30, 2024

LEEF Brands Announces 10:1 Share Consolidation and CAD $2,500,000 Capital Raise

Written by Customer Service on . Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S. VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) — LEEF Brands, Inc. (“LEEF” or the “Company”) (CSE: LEEF) (OTC: LEEEF) is pleased to announce a 10-for-1 share consolidation (the “Consolidation”) of the Company’s common shares, as well as a proposed private placement to raise up to $2,500,000 (the “Financing”). Share Consolidation Details: The Consolidation will consolidate the Company’s issued and outstanding common shares based on ten pre-consolidation shares for one post-consolidation share. The Consolidation aims to improve the Company’s capital structure, increase its attractiveness to institutional investors, and provide a more stable trading platform. Upon completion of the Consolidation, the Company will have approximately 162,762,651...

Continue reading

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Written by Customer Service on . Posted in Public Companies.

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the pricing of its “reasonable best efforts” public offering with a health-care focused institutional investor for the purchase and sale of up to 2,950,820 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,950,820 shares of common stock at a combined offering price of $1.525 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting...

Continue reading

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

Written by Customer Service on . Posted in Public Companies.

SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company’s common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder....

Continue reading

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

Written by Customer Service on . Posted in Dividend Reports And Estimates.

FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company’s revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo’s sales to its industrial customers, which includes biotech and pharmaceutical companies, increased 46% driven by our drug development and cell and gene therapy focus. The Company’s FY24 gross margin was 46%. The prior year gross margin of 37% included a one-time inventory provision of finished goods. The 900-basis point improvement was driven by the non-repeating...

Continue reading

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Written by Customer Service on . Posted in Public Companies.

BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $300.0 million. In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 1,071,428 shares of Class A common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October...

Continue reading

5E Advanced Materials Expands Commercial Team With Strategic Hire to Target APAC Specialty Glass Market

Written by Customer Service on . Posted in Public Companies.

Seasoned addition to commercial team will support 5E’s efforts to expand offtake agreements in the APAC region, and expand the scope of commercial contracting discussions HESPERIA, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) — 5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX: 5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, announced the appointment of Kenneth Hoo to its commercial strategy team.   Mr. Hoo joins the Company as its Vice President of Commercial Products – APAC, bringing more than 17 years of borates industry experience to the organization, having held several roles in a sales capacity at the largest global borate producers, as well as consumers. Most recently, Mr. Hoo served as a Sales Manager at Rio Tinto where he...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.